Ifabotuzumab

Tax included
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (KD=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10+ cells and improves pulmonary fibrosis.
MedChemExpress 
HY-P99655

Data sheet

Size
Multiple sizes
Reactivity
Ephrin Receptor; Apoptosis
Application
Cancer-Kinase/protease
CAS
2147698-66-4